- Home
- AVIR vs CBAN Comparison
AVIR vs CBAN Comparison
Compare AVIR & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- CBAN
- Stock Information
- Founded
- AVIR 2012
- CBAN 1975
- Country
- AVIR United States
- CBAN United States
- Employees
- AVIR N/A
- CBAN N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- CBAN Major Banks
- Sector
- AVIR Health Care
- CBAN Finance
- Exchange
- AVIR Nasdaq
- CBAN Nasdaq
- Market Cap
- AVIR 273.0M
- CBAN 287.3M
- IPO Year
- AVIR 2020
- CBAN 1998
- Fundamental
- Price
- AVIR $3.73
- CBAN $17.45
- Analyst Decision
- AVIR Hold
- CBAN
- Analyst Count
- AVIR 1
- CBAN 0
- Target Price
- AVIR $6.00
- CBAN N/A
- AVG Volume (30 Days)
- AVIR 407.1K
- CBAN 61.1K
- Earning Date
- AVIR 08-06-2025
- CBAN 07-23-2025
- Dividend Yield
- AVIR N/A
- CBAN 2.59%
- EPS Growth
- AVIR N/A
- CBAN 14.66
- EPS
- AVIR N/A
- CBAN 1.43
- Revenue
- AVIR N/A
- CBAN $113,756,000.00
- Revenue This Year
- AVIR N/A
- CBAN $18.25
- Revenue Next Year
- AVIR N/A
- CBAN $7.59
- P/E Ratio
- AVIR N/A
- CBAN $12.16
- Revenue Growth
- AVIR N/A
- CBAN 3.33
- 52 Week Low
- AVIR $2.46
- CBAN $12.65
- 52 Week High
- AVIR $4.15
- CBAN $18.49
- Technical
- Relative Strength Index (RSI)
- AVIR 74.60
- CBAN 73.26
- Support Level
- AVIR $3.63
- CBAN $17.26
- Resistance Level
- AVIR $3.78
- CBAN $18.01
- Average True Range (ATR)
- AVIR 0.14
- CBAN 0.39
- MACD
- AVIR 0.02
- CBAN 0.19
- Stochastic Oscillator
- AVIR 100.00
- CBAN 97.17
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.